Crescent Biopharma surged over 40% pre-market after announcing a strategic partnership with Sichuan Kelun-Biotech to accelerate its global oncology pipeline and combination strategy. The company also unveiled a $185 million private placement closing in early December, strengthening its cash runway. Crescent expects three programs to enter the clinic in 2026, highlighting strong pipeline momentum.